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Background: The melanocortin-4 receptor (MC4R) is part of an important pathway regulating
energybalance.Herewereport theexistenceofautoantibodies (autoAbs) against theMC4R in sera
of obese patients.
Methods: The autoAbs were detected after screening of 216 patients’ sera by using direct and
inhibition ELISA with an N-terminal sequence of the MC4R. Binding to the native MC4R was
evaluated by flow cytometry, and pharmacological effects were evaluated by measuring adenylyl
cyclase activity.
Results: Positive results in all tests were obtained in patients with overweight or obesity (preva-
lence, 3.6%) but not in normal weight patients. The selective binding properties of anti-MC4R
autoAbs were confirmed by surface plasmon resonance and by immunoprecipitation with the
native MC4R. Finally, it was demonstrated that these autoAbs increased food intake in rats after
passive transfer via intracerebroventricular injection.
Conclusion: These observations suggest that inhibitory anti-MC4R autoAbsmight contribute to
the development of obesity in a small subpopulation of patients. (J Clin Endocrinol Metab 94:
793–800, 2009)
In previous experiments we have shown that active immuniza-tion of rats against a 15-amino acid sequence of the N-ter-
minal (NT) domain of the melanocortin-4 receptor (MC4R) re-
sults in a mild form of obesity and insulin resistance (1), which
was more pronounced under a high-fat diet (2). These findings
are consistent with observations by other authors that the NT
domain of the MC4R is essential for the function of the MC4R
and is involved in themaintenance of its constitutive activity (3).
In further in vitro experiments, we could demonstrate that anti-
MC4R antibodies (Abs) acted as inverse agonists and as non-
competitive antagonists (1). The passive transfer of purified Abs
in vivo by intracerebroventricular (icv) injection in rats induced
an increase in food intake (1).
These experimental findings prompted us to hypothesize that
autoAbs against the MC4R might exist in a subpopulation of
obesepatients andcontribute to thedevelopmentof their disease.
It has been reported that autoAbs against peptides such as
-MSH may be involved in the pathogenesis of eating disorders
(4, 5). Inhibitory autoAbs against theMC4Rwould be expected
to increase appetite and might thereby be of pathophysiological
significance (6–9). In this paper we report for the first time the
presenceof inhibitory autoAbs against theMC4R inhuman sera.
The fact that such Abs were only found in patients with over-
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weight or obesity and blocked the activity of theMC4R suggests
that such anti-MC4R autoAbs might contribute to the patho-
physiology of obesity.
Patients and Methods
Human sera
Sera were obtained from 129 patients at the Stadtklinik, Mediz-
inische Klinik I, Baden-Baden, Germany, who suffered from metabolic
diseases (e.g. type 2 diabetes) but were free from acute illness and had
different body mass index (BMI): obese (OB), BMI 30 kg/m2, n 34;
overweight (OW), 25  BMI  30 kg/m2, n  43; and normal weight
(NW), BMI  25 kg/m2, n  52. Additional sera were obtained from 84
patients consecutively admitted to the University Hospital, Strasbourg,
France. These patients also suffered frommetabolic diseases including dis-
orderswith an autoimmune background (e.g. type 1 diabetes,Hashimoto’s
disease) andhaddifferentBMI:OB,n46;OW,n17; andNW, n 24.
Basic information on the total patient population is summarized inTable
1.The serawere coded, andall screening experimentsweredone in a fully
blinded way. The studies were approved by the local ethical committees
of France and Germany.
NT peptides
Peptides corresponding to the NT domain of the humanMC3R and
MC4R (FSNQSSSGFCEQVFIKPEV andKTSLHLWNRSSHGLHG, re-
spectively)weredesignedand synthesizedasdescribedpreviously (1, 10).
Direct and inhibition ELISA
The direct ELISA procedure has been described previously (11). To
confirm the signal observed in the direct ELISA, an inhibition ELISAwas
used to titrate the positive sera preincubated with increasing concentra-
tions (2  1012 to 2  106 M) of the MC4R NT peptide in solution.
Specificity was defined as an inhibition of at least 20% (11).
Ig precipitation
IgG fractions were prepared from 500 l of serum samples by am-
monium sulfate precipitation at a final saturation of 33%. After precip-
itation, sera were placed on ice for 1 h and centrifuged at 10,400  g
during 20 min. The pellets were resuspended with 300 l of PBS and
dialyzed at 4 C against PBS for 96 h.
Human embryonic kidney 293 (HEK-293) cell culture
HEK-293 cells overexpressing the human MC4R (HEK-hMC4R)
were cultured in DMEM (Sigma, St. Louis, MO) completed with 10%
fetal calf serum (Bioconcept, Allschwil, Switzerland), 1% penicillin/
streptomycin (GIBCO, Grand Island, NY), and 600 g/ml G418 anti-
biotic (Sigma) in a humidified atmosphere containing 5% CO2 at 37 C.
Fluorescence-activated cell sorting (FACS)
To check whether the Abs present in the IgG fraction were able to
recognize the hMC4R, flow cytometry assays were performed as de-
scribed previously (12). Twenty-eight IgG fractions from direct ELISA
positive sera were tested.
Adenylyl cyclase (AC) assay
To assess the ability of autoAbs to modulate the MC4R activity, AC
assays were performed onHEK-hMC4R cells. In addition, purified anti-
MC4RautoAb fractions fromtwopatients,A69andB6,were tested. IgG
fractions were considered as positive when the AC activity was signifi-
cantly decreased below basal levels in the absence of-MSHorwhen the
EC50 values were significantly shifted to the right in the presence of
-MSH. All data were expressed as mean  SEM.
Purification of anti-MC4R autoAbs
The anti-MC4R autoAbs were affinity-purified by using NT-peptide
coupled via the N terminus to a cyanogen bromide-activated Sepharose
4Bcolumn (AmershamBiosciences,Uppsala, Sweden) according toman-
ufacturer’s instructions. Sera were loaded on the column at 4 C. The Abs
were eluted with 0.2 M glycine (pH 2.7), collected in tubes containing 1
M Tris buffer (pH 8.0), subsequently dialyzed against PBS overnight at 4
C, and stored at 20 C.
Depletion of IgG and anti-MC4R autoAbs
The serum of an individual OW patient (A57) was used in these
experiments. It was incubated overnight with cyanogen bromide-acti-
vated Sepharose beads (Amersham Biosciences) saturated with glycine.
Subsequently, the serumwas incubated overnight with protein A/G aga-
rose orNT-peptide conjugated to Sepharose beads. The supernatantwas
precipitated and tested in an AC assay.
Surface plasmon resonance experiments
Assays were performed in the BIACORE 3000 system as described
previously (1).Kinetic parameters of the interactionbetweenanti-MC4R
autoAbs from patients A69 and B6 were measured at 25 C in two series
of experiments. First, five different concentrations (0.25–4 M) of pu-
rified anti-MC4R autoAbs from patient A69 were injected at a flow rate
of 30 l/min for 300 sec on the immobilized MC4R NT peptide and
MC3R NT peptide as control, followed by a dissociation phase of 400
sec. Subsequently, five different concentrations (0.125–1M) of purified
anti-MC4R autoAbs from patient B6 were injected at a flow rate of 30
l/min for 300 sec on the immobilized NT peptides, followed by a dis-
sociation phase of 400 sec. The kinetic parameters were calculated using
BIAevaluation software 4.1 (GE Healthcare, Uppsala, Sweden). All RU
values obtained with the control MC3R NT peptide were subtracted
from those obtained with the MC4R NT peptide to compensate for
nonspecific binding.
Membrane preparations
HEK-293 cells stably transfected with the hMC4R or hypothalami
frommaleSprague-Dawley ratswerepreparedasdescribedpreviously (13).
Immunoblotting
Membrane proteins were denatured for 5 min by boiling in loading
buffer without -mercaptoethanol, subjected to electrophoresis on a
10% polyacrylamide gel containing sodium dodecyl sulfate, and finally
electrotransferred onto nitrocellulosemembranes. Human IgG fractions
diluted 1:5000 in PBS-Tween 3% nonfat dry milk were applied to the
membraneand revealedusingperoxidase conjugatedgoat antihumanAb
(Jackson Immunoresearch Laboratories, San Diego, CA) (1:5000) and
ECL plus™ reagent (Amersham Bioscience).
Immunoprecipitation
MC4Rmembrane preparations (10g)were incubatedwith purified
human anti-MC4R autoAbs (25 g) overnight at 4 C. The mixture was
immunoprecipitated with 25 l of protein A/G agarose. The immuno-
precipitated samples were loaded on a 4–15% gradient gel (Bio-Rad,
Hercules, CA) and transferred onto nitrocellulosemembranes. The pres-
ence of MC4R was detected by using polyclonal anti-MC4R Abs (Ab-
TABLE 1. Characteristics of patient population
OB
(n  80)
OW
(n  60)
NW
(n  76)
Age (yr) 62.6  13.9 67.4  14.7 59.8  16.7
Females/males (n) 49/31 27/33 46/30
BMI (kg/m2) 35.9  4.3 26.9  1.4 22.0  1.7
Data are presented as mean  SD.
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cam, Cambridge, UK) in the standard procedure described in the One-
Step Complete IP-Western kit (Genscript, Piscataway, NJ).
Icv injection in rats
Male Sprague-Dawley rats (275–325 g)with a chronically implanted
catheter in the third cerebral ventricle were used (1). Purified autoAbs
from patient A69 or B6 were slowly (1 min) injected icv at 0900 h at a
dose of 0.1 g or 1.0 g in a volume of 2 l using a Hamilton syringe.
These doses were selected based on the results of comparative in vitro
studies. Control rats received BSA. After the injection of autoAbs and
BSA, food intake was continuously recorded during the following 48 h
using an automatic food intake apparatus (TSE Systems, BadHomburg,
Germany).
Statistical analysis
AC assay results were analyzed by Fisher test using GraphPad Prism
4 software (GraphPad Software Inc., La Jolla, CA). Proportions were
analyzed using proportion z-test. Kruskal-Wallis test was used for the
analysis of ELISA optical density and for percentage of fluorescent cells
in FACS experiments.
Results
Patient characteristics and screening procedure
The patient characteristics and the results of the sequential
screeningofpatients’ seraare shown inTables1and2, respectively.
Immunoreactivity against the NT peptide
Among the 216 sera collected from patients with metabolic
diseases, 28 (13%) contained IgGAbs that interactedwith theNT
peptideof theMC4RinadirectELISA.Sixteenof thesepositivesera
were fromOB,nine fromOW,andthree fromNWindividuals (Fig.
1A). The prevalence of circulating anti-NT autoAbs as determined
by direct ELISA was 20% in OB, 15% in OW, and 3.9% in NW
individuals. The median OD450nm values were significantly higher
in OB and OW than in NW individuals (Fig. 1B).
The positive signal obtained in 28 sera by direct ELISA was
confirmed for 12 sera by using inhibition ELISA. Seven of these
sera came from OB, three from OW, and two from NW indi-
viduals (Fig. 1C). The prevalence of circulating anti-NTautoAbs
as determined by inhibition ELISAwas 8.8% inOB, 5% inOW,
and 2.6% in NW individuals.
Immunoreactivity against the MC4R
IgG fractions from the 12 sera containing anti-NT autoAbs
were tested for their ability to bind to HEK-hMC4R cells in
FACSexperiments. Fiveof the12 IgGfractions labeledHEK-293
cells. Three came from OB and two from OW individuals (Fig.
1D). Three of these autoAbs belonged to the German and two to
the French patient population. The prevalence of circulating an-
ti-MC4RautoAbswas3.8%inOBand3.3%inOWindividuals.
No such autoAbs were found in sera of NW individuals.
Pharmacological activity
AC assay
Under basal conditions, the IgG fractions tended to reduce
cAMP production; the changes were small but significant (P 
TABLE 2. Sequential screening steps and numbers of sera tested
Step I (direct ELISA with NT peptide) was designed to detect the presence of anti-NT IgG. Step II (inhibition ELISA with NT peptide) was used to confirm the signal
obtained in step I. Step III (FACS) was designed to determine whether the Abs detected in steps I and II recognized the native MC4R. Step IV (AC assay) was designed to
assess the functional activity of the Abs. Results are presented as numbers of positive sera from OB, OW, and NW individuals.
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0.01, F-test) (Fig. 1E). When fixed dilutions of the IgG fractions
were studied in the presence of increasing concentrations of
-MSH, the concentration-response curvewas significantly (P
0.001, F-test) shifted to the right, and the maximum effect of
-MSH was reduced (Fig. 1F). No IgG fraction from NW indi-
viduals had such an effect (data not shown). The prevalence of
inhibitory autoAbs against the hMC4R in the combinedOB/OW
population was 3.6%.
Specificity of the pharmacological activity
For these experiments, an anti-MC4R autoAb fraction from
the serumofa singleOWindividualwas studied inHEK-hMC4R
cells. The anti-MC4R autoAb fraction inhibited basal AC activ-
ity in a concentration-dependent manner, i.e. it acted as an in-
verse agonist (Fig. 2A). General and specific IgG depletion sig-
nificantly decreased the inverse agonist activity, suggesting that
it was due to the presence of anti-MC4R autoAbs (Fig. 2A).
AC activity was also measured in the presence of increasing
concentrations of-MSH.Under these conditions, the anti-MC4R
autoAb fraction shifted the concentration-response curve to the
right anddecreased themaximumefficacyof-MSH, i.e. it actedas
a noncompetitive antagonist (Fig. 2B). General or specific IgG de-
pletionrestored the full effectsof-MSH,suggesting that theblock-
ade was due to the presence of anti-MC4R autoAbs (Fig. 2B).
Comparison of autoAbs from two individual patients
Two patients’ serawere selected for comparative studies, and
anti-MC4R autoAbs were purified by using specific immunoad-
sorption. PatientB6 serumwaspositive in all four screening tests,
whereas patient A69 serum was positive in the direct and inhi-
A B
C D
E F
FIG. 1. Results of screening assays. A, Results of direct ELISA presented as percentage of positive sera in each BMI group. The prevalence of positive sera was
approximately four times higher in OB and OW than in NW individuals (**, P  0.01; ***, P  0.001; proportion z-test). B, Optical density in positive sera. The median
OD450nm values were higher in sera from OB and OW than from NW individuals (*, P  0.05, Kruskal-Wallis test). C, Results of inhibition ELISA presented as
percentage of positive sera in each BMI group. The prevalence of positive sera was approximately four times higher in OB [(*), P  0.057; proportion z-test] than in NW
individuals. D, Percentage of fluorescent cells detected in positive sera from FACS experiments; the dotted line indicates the calculated threshold. The number of
fluorescent cells was higher in OB than in NW individuals (*, P  0.05, Kruskal-Wallis test). E, Effects of all FACS-positive IgG fractions (Œ) on cAMP production in HEK-
hMC4R cells under basal conditions. There was a concentration-dependent reduction in cAMP production, suggesting an inverse agonist activity (**, P  0.01, F-test).
F, Effects of a 1/100 dilution of all FACS-positive IgG fractions (Œ) on cAMP production upon treatment with increasing concentrations of the MC4R agonist -MSH.
Control experiments were performed with PBS (f). The IgG fractions shifted the concentration-response curve significantly (***, P  0.001, F-test) to the right and
decreased the maximum effects of -MSH, suggesting a noncompetitive antagonist activity. Mean  SD of five different sera measured in triplicate.
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bition ELISA but negative in the FACS and AC assays. Thus
serum B6 contained autoAbs that recognized both the NT pep-
tide and the native hMC4R, whereas serum A69 contained au-
toAbs that recognized only the NT peptide.
Surface plasmon resonance with the NT peptide
Purified anti-MC4RautoAbs frompatientA69 in solutionwere
tested for binding to the immobilized NT peptide. Specific binding
was obtained at a relatively high KD (1.2 10
5 M). When tested
under the same conditions, purified anti-MC4R autoAbs from pa-
tient B6 showed specific binding with approximately 20 times
higher affinity (KD 6.0 10
7 M).
Immunoprecipitation of the native MC4R
The interaction of the anti-MC4R autoAbs with the native
human or rat MC4R was assessed in immunoprecipitation ex-
periments. The autoAbs from patient B6 precipitated both hu-
man and rat MC4Rs (Fig. 3). In contrast, autoAbs from patient
A69 failed to precipitate the MC4R in membrane preparations
from either HEK-hMC4R cells or rat hypothalami (Fig. 3).
In vitro effects on AC activity
Purified anti-MC4R autoAbs were tested in the AC assay to
assess their pharmacological effects on the stimulation ofMC4R
activity by -MSH. Purified autoAbs from patient B6 decreased
significantly the maximum effect of -MSH (Fig. 4A). In contrast,
autoAbspurified fromserumofpatientA69were inactive (Fig.4A).
In vivo effects on food intake
Purified anti-MC4RautoAbswere tested in vivo
by a single injection of a dose of 0.1 or 1g into the
third cerebral ventricleof rats. Food intakewas con-
tinuously measured over the subsequent 48 h. A
dose of 0.1 g was not effective (data not shown).
In rats treated with 1 g autoAbs from patient B6,
48-h food intake was 10% higher than in those
treated with autoAbs from patient A69 or in con-
trols receiving BSA (Fig. 4B).
Discussion
Theexistenceof autoAbsagainstGprotein-coupled
receptors is becoming widely recognized, and the
number of reports on diseasesmediated by autoAbs
is increasing (14–16). However, the detection of
autoAbs is fraught withmethodological issues, and
the proof of a causal relationship between autoAbs
and symptoms requires the demonstration of bio-
logical activity in functional assays (17, 18). In our
studies on human blood samples, we could take
advantage of our previous experience with MC4R
immunization (1, 2). We chose a direct ELISA fol-
lowed by an inhibition ELISA as the initial assays to
detect possible autoAbs directed against theNTdo-
main of the MC4R. Because in both assays the NT
peptide was used as the bait, Abs binding to any
conformation of this 15-amino acid sequence
would give a positive signal. To detect only autoAbs that recog-
nized the NT sequence in its native conformation, cells express-
ing the hMC4Rwere studied by using FACS. Finally, ACactivity
measurements were used to assess the pharmacological proper-
ties of these autoAbs.
At each step in the screening procedure, the prevalence of
positive sera was higher in OB and OW patients than in NW
patients. This difference in prevalence was 17.8% inOB/OW vs.
3.9% in NW individuals after the first ELISA test. Moreover,
positive sera showed higher anti-NT immunoreactivity as indi-
catedby thehigherODvalues. The difference between the prev-
alence of positive sera in OB/OW vs. NW individuals was
smaller in the following inhibition ELISA (7.1 vs. 2.6%). In
the subsequent FACS assay in which binding of purified IgG
fractions to the native MC4R was determined, only IgG frac-
tions from sera of OB or OW patients gave positive results (5
of 140, prevalence in OB/OW patients: 3.6%). All IgG frac-
tions that were positive in the FACS assay showed inhibitory
activity in AC assays. IgG fractions from NW patients had no
such effects.
In the present study, the dependence of the pharmacological
effects of the autoAb fractions on the presence of IgGs was dem-
onstrated in vitro. For this purpose, an anti-MC4R autoAb frac-
tion from a single OW patient was used. Under control condi-
tions, this fraction showedpharmacological activity as an inverse
agonist and a noncompetitive antagonist of the MC4R. After
general depletion of all IgG or specific depletion of anti-MC4R
A
B
FIG. 2. General and specific IgG depletion. A, Effects of an IgG fraction (44 mg/ml) from a single
OW individual (Œ) on cAMP production in HEK-hMC4R cells under basal conditions. The depletion
of IgGs with either NT- () or protein A/G- () coated beads eliminated the inverse agonist
activity (**, P  0.01, z-test). B, Effects of a 1:100 dilution of an IgG fraction from a single OW
individual (Œ) on cAMP production upon treatment with increasing concentrations of the MC4R
agonist -MSH. Control experiments were performed with PBS (f). The IgG fraction shifted the
concentration-response curve to the right and decreased the maximum effects of -MSH. The
depletion of IgGs with either NT- () or protein A/G- () coated beads eliminated the
noncompetitive antagonist activity (***, P  0.001, z-test). Mean  SD of triplicate
measurements.
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IgGs from this fraction, its pharmacological activity was lost.
These findings strongly suggest that the inhibitory effects of this
fraction on the MC4R were due to the fact that it contained
anti-MC4R autoAbs.
For a detailed evaluation of the physicochemical, biochemical,
and pharmacological properties of autoAbs, sera of two OB pa-
tients were compared. One serum (B6) was positive in all four
screening steps, whereas the other one (A69) was positive in the
initial twoELISAtestsbutnegative in the subsequentFACSandAC
assays. Serum B6 was therefore considered to contain inhibitory
autoAbs against the native hMC4R, whereas serumA69 served as
a control that was supposed to contain autoAbs against the NT
peptide.
Surface plasmon resonance revealed binding to the NT do-
main for both sera, but autoAbs from patient B6 had a much
higher affinity than those from patient A69. The dissociation
constant for B6 was in the range of that observed with neutral-
izing Abs against other peptidic antigens (19). The difference in
affinity between B6 and A69 may explain why only B6 autoAbs
gave positive results in the tests using the native MC4R.
Immunoprecipitation is widely regarded as the most reliable
method to demonstrate the existence of autoAbs (18). Artifacts
are minimized by the fact that an antigen must be coprecipitated
with an Ab before it is revealed by Western blotting. This pro-
cedure ensures that a specific binding step is followed by the
specific identification of the bound molecule. Anti-MC4R auto-
Abs from patient B6 coprecipitated human and rat MC4Rs,
whereas those from patient A69 were inactive. This result
strongly suggests that B6 autoAbs specifically and strongly
interacted with the NT domain of the MC4R in its native
configuration.
Finally,we performedwith the human autoAbs the same type
of in vivo experiment that had been done with rat and rabbit
anti-MC4R Abs (1, 2). After an icv injection in rats of autoAbs
from patient B6, food intake gradually increased above the val-
ues seen after injection either of autoAbs from patient A69 or of
BSA.The effects on food intake in theB6 groupdeveloped slowly
and were significant by 48 h after injection. At that time, food
intake was 10% higher in B6-treated than A69-treated rats.
There was no difference between the A69 group and the BSA-
treated control group. Comparedwith our previous studies with
rat anti-MC4R Abs, the effect occurred in the same dose range
(1g), and itsmagnitude and time coursewere of the same order
of magnitude as seen with rat or rabbit anti-MC4R Abs (1, 2).
Taken together, the serum samples from patient B6 gave pos-
itive results in four screening assays (direct and inhibitionELISA,
FACS, and AC), in two additional in vitro experiments (surface
plasmon resonance, immunoprecipitation), and in one in vivo
study (food intake in rats). In all instances the effects were con-
sistent with what would be expected from potent and specific
inhibitory anti-MC4R autoAbs. We do not know whether the
FIG. 3. Immunoprecipitation of the human and rat MC4R (hMC4R and rMC4R,
respectively). Lanes a and e show the hMC4R (prepared from HEK-hMC4R cells)
and the rMC4R (prepared from rat hypothalami) as detected by commercially
available polyclonal anti-MC4R Abs. Lanes b and c show the results obtained
with hMC4R and purified anti-MC4R autoAbs from patients B6 or A69, whereas
lanes f and g show the corresponding results with rMC4R. Lanes d and h show
control experiments without Abs. The purified anti-MC4R autoAbs from patient
B6 precipitated both the hMC4R (b) and the rMC4R (f), whereas those from
patient A69 were inactive.
A
B
FIG. 4. Pharmacological activity of anti-MC4R autoAbs in vitro and in vivo. A,
Effects of anti-MC4R autoAbs (10 nM) from patient B6 (Œ) or A69 () on cAMP
production upon treatment with increasing concentrations of the MC4R agonist
-MSH. Control experiments were performed with PBS (f). The anti-MC4R
autoAbs from patient B6 significantly (***, P  0.001, z-test) decreased the
maximum efficacy of -MSH, whereas those from patient A69 were inactive.
Mean  SD of five measurements per curve. B, 48-h food intake in rats that
received icv injections of purified anti-MC4R autoAbs from patients B6 and A69
or BSA (1 g in 2 l). Rats injected with anti-MC4R autoAbs from patient B6
(n  21) showed a significant increase in food intake as compared with those
injected with autoAbs from patient A69 (n  19) or with BSA (n  22). Data are
presented as means  SEM [(*), P  0.059; *, P  0.05; repeated measures two-
way ANOVA with Bonferroni post hoc test].
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autoAbs from all patients’ sera with positive screening results
show the same effects. However, it seems reasonable to assume
that the serum from patient B6 was representative because it
shared the same properties in the four screening tests with the
other positive sera.
It can only be speculated how autoAbs against theMC4R are
generated. Possible explanations are conformational similarities
(antigenmimicry) of theNT sequencewith exogenous infectious
agents or with endogenous antigens generated via necrosis or
degradation of related molecules (20, 21). Recent findings sug-
gest that a potential source of antigens could be the gut flora (22,
23). This reservoir contains an enormous amount of structures
with possible homology to endogenousmolecules. The initiation
andmaintenance of an immune response depends on various not
well-defined associated conditions (24, 25), and different envi-
ronmental factors could have a modulating effect.
CirculatingautoAbsagainst theMC4Rcanonlybecomepatho-
physiologicallyactive if theyenter thebrain.Thusan impaired func-
tion of the blood-brain barrier would be the prerequisite for the
penetration of autoAbs into the brain tissue. This may occur more
frequently than generally assumed because the tightness of the
blood-brain barrier can be compromised not only by serious con-
ditions such as trauma or epileptic seizures but also bymore subtle
disturbances such as psychological stress (26, 27). Whether the
blood-brainbarrier in thehypothalamicarea is leakyor evenabsent
is a matter of debate (28, 29). After acute systemic administration
of Abs, a small fraction (0.1%) has been found to penetrate into
brain tissuewithin 1h (30).During chronic treatment, this percent-
age may be higher. Moreover, complete monoclonal Abs against
amyloid -peptide and F(ab)2 fragments thereof have been shown
to enter the central nervous systemat therapeutically relevant levels
(31, 32). Finally, our previous experiments in rats strongly suggest
that Abs must have passed the blood-brain barrier because the ac-
tively immunized rats developed a phenotype that was consistent
with blockade of hypothalamic MC4Rs (1, 33).
Because the anti-MC4R autoAbs observed in our present
study reduced but did not completely eliminate the activity of the
MC4R under basal and stimulated conditions, the functional
disturbances caused by such autoAbs will probably be generally
less pronounced than those seen in genetically mediated cases of
impaired MC4R function. Conversely, it may be assumed that
autoAbs will only play a significant pathophysiological role if
they are directed against targets that are essential for the control
of energy balance. AutoAbs against less important targets or
againstmediators that can be compensated forwill probably not
result in manifest disease.
The fact that the prevalence of autoAbs against the NT pep-
tide or the MC4R segregated with BMI and that functionally
active autoAbs were present in OW and OB but not in NW
subjects strongly suggests a possible pathogenic role in the de-
velopmentofobesity.However, anassociationbetween theprev-
alence of autoAbs and BMI in a cross-sectional study does not
prove a causal relationship. Additional studies are necessary to
determine the precise prevalence of anti-MC4R Abs in OB pa-
tients and to prove their pathophysiological significance. If our
present findings could be confirmed in such longitudinal studies,
they could help to develop novel diagnostic tools and design
individualized treatment for a subpopulation of patients with
obesity.
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